Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

NCT06945523 | Recruiting Phase 1

• 1 other identifier: PBC082
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Lung cancer is the leading cause of morbidity and mortality in the world, of which 80%-85% are non-small cell lung cancer (NSCLC). Most patients with NSCLC are at the advanced stage of diagnosis and have a poor prognosis. The 5-year survival rate of stage III patients is about 15%, the 5-year survival rate of stage IV patients is less than 5%, and the median survival time is only 7 months. CEACAM5 (CEA), also known as CD66e, is a classic tumor marker that has been used as a marker for many types of tumors for 50 years. It is mainly expressed in lung cancer, esophageal cancer, bile duct cancer, colorectal cancer, gastric cancer and other tumor types. In previous CAR-T-related clinical trials targeting CEA, the research team found that CAR-T cell preparations had a certain killing effect on CEA positive tumor cells. At the same time, CAR-T cell preparations cannot be sustained for a long time in the body, which is also a key factor restricting the anti-tumor effect of CAR-T cells in the body. To solve this problem, the killing ability and survival ability of CAR-T cell preparations on tumor cells in vitro and in vivo were improved by optimizing CAR structure and improving culture mode.

Conditions

Advanced Lung Cancer

Keywords

CEA; CAR-T; Advanced Lung Cancer

Outcome Measures

Primary Outcomes (1)

• To evaluate the safety and tolerability of CAR T cell preparations in the treatment of CEA positive advanced lung cancer【safety】

  Adverse events and their proportion during the trial (assessed against the Common Terminology Standard for Adverse Events Version 5.0 (CTCAE 5.0) and ASTCT standards)

  28days

Secondary Outcomes (8)

• To evaluate the disease control rate of CAR-T cell preparations in CEA positive advanced lung cancer【efficacy】

  3months

• To evaluate the remission rate of CAR-T cell preparations in CEA positive advanced lung cancer【efficacy

  3months

• To evaluate the overall survival of CAR-T cell preparations in CEA-positive advanced lung cancer【efficacy】

  2years

• To evaluate the duration of response of CAR-T cell preparations in CEA-positive advanced lung cancer【efficacy】

  2years

• To evaluate the disease progression-free survival of CAR-T cell preparations in CEA-positive advanced lung cancer【efficacy】

  2years

Study Arms (2)

Targeted CEA CAR-T intravenous infusion group

EXPERIMENTAL

Biological: Targeted CEA CAR-T

Targeting CEA CAR-T pleural infusion group

EXPERIMENTAL

Biological: Targeted CEA CAR-T

Interventions

Targeted CEA CAR-T BIOLOGICAL

Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest

Targeted CEA CAR-T intravenous infusion group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years, regardless of gender.
• Histologically or cytologically confirmed diagnosis of advanced, metastatic, or recurrent lung cancer, including both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
• Disease progression or intolerance following at least one line of prior therapy (including but not limited to surgery, chemotherapy, radiotherapy, targeted therapy, or immunotherapy).
• For patients with pleural effusion enrolled in the intrapleural infusion group, accurate assessment of pleural effusion volume and characteristics must be conducted via imaging (chest CT or X-ray) combined with cytological analysis. Cytological examination must confirm the presence of tumor cells in the pleural effusion, indicating malignant pleural effusion.
• Positive tumor CEA expression confirmed by immunohistochemistry (IHC) within 3 months prior to screening (defined as clear membranous staining with a positivity rate ≥10%). If IHC testing of tumor samples was performed more than 3 months prior to screening, the patient's serum CEA must be \>10 ng/mL.
• At least one measurable lesion according to RECIST 1.1 criteria: for non-nodal lesions, the longest diameter must be ≥10 mm; for nodal lesions, the short axis must be ≥15 mm.
• ECOG performance status score of 0-2.
• Expected survival of more than 12 weeks.
• No severe psychiatric disorders.
• Unless otherwise specified, key organ functions must meet the following requirements:
• Hematologic: WBC \>2.0×10⁹/L, neutrophils \>1.0×10⁹/L, lymphocytes \>0.5×10⁹/L, platelets \>50×10⁹/L, hemoglobin \>80 g/L;
• Cardiac function: Left ventricular ejection fraction (LVEF) ≥50% by echocardiography, and no significant abnormalities on ECG;
• Renal function: Serum creatinine ≤2.0×ULN;
• Hepatic function: ALT and AST ≤3.0×ULN (≤5.0×ULN if liver metastases are present);
• Total bilirubin ≤2.0×ULN;

You may not qualify if:

• Presence of symptomatic central nervous system (CNS) metastases or leptomeningeal metastases at screening, or other evidence indicating that CNS or leptomeningeal lesions are not adequately controlled, making the patient unsuitable for enrollment as judged by the investigator.
• Participation in another clinical study within 1 month prior to screening.
• Receipt of a live attenuated vaccine within 4 weeks prior to screening.
• Prior antitumor therapies before screening including: chemotherapy, targeted therapy, or other investigational drugs administered within 14 days or at least 5 half-lives (whichever is shorter) before screening.
• Active or uncontrolled infections requiring systemic treatment.
• Tumor compressing the trachea or major blood vessels with high risk as assessed by the investigator.
• Presence of any of the following cardiac conditions:
• New York Heart Association (NYHA) Class III or IV congestive heart failure;
• Myocardial infarction or coronary artery bypass graft (CABG) within 6 months prior to enrollment;
• Clinically significant ventricular arrhythmias or a history of unexplained syncope (excluding vasovagal or dehydration-related causes);
• History of severe non-ischemic cardiomyopathy.
• Active autoimmune diseases or other conditions requiring long-term immunosuppressive therapy.
• History of other untreated or concurrent malignancies within the past 3 years, except for adequately treated cervical carcinoma in situ or basal cell carcinoma of the skin.
• Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA levels exceeding the normal range in peripheral blood; positive hepatitis C virus (HCV) antibody with detectable HCV RNA levels exceeding the normal range in peripheral blood; positive for human immunodeficiency virus (HIV) antibodies; or positive syphilis test.
• Pregnant or breastfeeding women.

Sponsors & Collaborators

• Chongqing Precision Biotech Co., Ltd: lead

Study Sites (1)

Wuhan Pulmonary Hospital

Wuhan, Hubei, 430030, China

RECRUITING

Central Study Contacts

Shuang Wei, MD

CONTACT

18062087116; wsdavid2001@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 11, 2025
• First Posted: April 25, 2025
• Study Start: April 28, 2025
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): April 30, 2028
• Last Updated: June 4, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)